Editor of Patient Care Online.
FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
Your daily dose of the clinical news you may have missed.
Study: COVID-19 Pandemic Disruptions in Cancer Screening Show Uneven Recovery in 2023
Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.
Women as Young as Age 30 May Experience Perimenopause Symptoms: Daily Dose
Contact Dermatitis: Expert Insights on First-Line and Emerging Therapies
JiaDe 'Jeff' Yu, MD, discusses first-line therapies, emerging biologics, and the potential of molecular biomarkers for improved diagnosis.
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.
Elizabeth Swanson, MD: When HSV Causes Big Dermatologic Problems
Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."
Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.
The Complexities of Treating Rosacea, with Benjamin Ungar, MD
Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Patient Benefit Index Complements Traditional Psoriasis Outcome Measures, Study Finds
Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.
Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.
Study Reveals Persistent Telehealth Disparities in Depression Management: Daily Dose
Dupilumab Shows Efficacy in Eosinophilic Esophagitis Regardless of Food Elimination Diets
The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.
Shifting Trends in Severe Asthma Biologics: Daily Dose
GSK’s Depemokimab Applications Accepted for FDA Review for Asthma and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature
The Loss of Pulse Detection feature will begin rolling out in the US late next month.
Nektar Therapeutics Completes Enrollment for Phase 2b Alopecia Areata Trial
The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.
FDA Accepts Supplemental New Drug Application for Uzedy for Bipolar I Disorder
The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Transdermal Peanut Patch Shows Lasting Allergy Benefits: Daily Dose
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
Home-Based Therapy Achieves 100% Success Rate in Children with High-Threshold Peanut Allergy
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.
